$AGEN Reports Positive Clinical Results for Botensilimab/Balstilimab Combination in Non-MSI-H Colorectal and Recurrent Platinum-Resistant Ovarian Cancer Patients
Agenus Inc. announces promising results for its botensilimab/balstilimab combination in treating non-microsatellite instability-high colorectal and platinum-resistant ovarian cancer. The FDA has granted Fast Track Designation for the combination in non-MSI-H metastatic colorectal cancer. The company is conducting global Phase 2 trials and aims to commence a Phase 3 trial in 2023. Shareholders received a dividend of around 5M shares of its subsidiary, MiNK Therapeutics' stock, offering opportunities for direct ownership and growth. However, there are inherent risks and uncertainties in drug development that investors should consider.
$AGEN reports strong clinical pipeline and potential in combination therapy.
Agenus Inc. has announced positive financial results for Q4 2022 and the full year, showing strong momentum across its diverse clinical pipeline of immuno-oncology programs. Anchor programs botensilimab and balstilimab have shown exciting potential in combination to treat treatment-resistant cancers, generating significant interest from experts worldwide. AGEN2373 and botensilimab are expected to finish Phase 1b study dosing in H1 2023, with the potential launch of a randomized phase 3 study if response rates persist. AGEN1571 combination cohorts with botensilimab and balstilimab will begin in 2023 as well. The company holds a robust antibody discovery platform and GMP manufacturing facility, with a cash balance of $307M as of December 31, 2021. However, forward-looking statements in the official release have risks and uncertainties, so investors should proceed with caution.